Background: The Diagnostic Criteria for Psychosomatic Research (DCPR) have been demonstrated to be useful in identifying specific psychological conditions of medical patients. The aim of this study was to evaluate the clinical utility of the DCPR in predicting the treatment outcome of patients with functional gastrointestinal disorders (FGID). Methods: FGID outpatients were allocated to improved (n = 65) and unimproved (n = 40) groups on the basis of preestablished criteria following 6 months of treatment. Patients were administered the structured interview for DCPR at baseline and the Gastrointestinal Symptom Rating Scale both at baseline and follow-up. Results: In the unimproved patients, the prevalence of the DCPR categories of alexithymia (82.2%) and persistent somatization (72.5%) was significantly higher while health anxiety was more prevalent in improved patients (21.5%). No unimproved patient lacked a DCPR diagnosis while multiple DCPR diagnoses were significantly higher in the unimproved group (90%). In the regression analysis, alexithymia, persistent somatization, a higher number of DCPR diagnoses for each patient and, to a lesser extent, greater symptom severity at baseline were significant predictors of unimprovement. Health anxiety, even after controlling for gastrointestinal symptoms, was a significant predictor of improvement. Conclusion: The ability to predict treatment outcome indicates the clinical utility of the DCPR. Clinicians may improve treatment outcome for FGID patients by identifying particular psychosomatic syndromes (alexithymia, persistent somatization, and health anxiety) and patients with multiple DCPR clusters, and attempting to address specific therapeutic interventions.

1.
Fava GA, Freyberger HJ, Bech P, Christodoulou G, Sensky T, Theorell T, Wise TN: Diagnostic criteria for use in psychosomatic research. Psychother Psychosom 1995;63:1–8.
2.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
3.
World Health Organization: The ICD-10 Classification of Mental and Behavioural Disorders. Geneva, WHO, 1992.
4.
Fava GA, Mangelli L, Ruini C: Assessment of psychological distress in the setting of medical disease. Psychother Psychosom 2001;70:171–175.
5.
Fava GA: The concept of psychosomatic disorder. Psychother Psychosom 1992;58:1–12.
6.
Lipowski ZJ: Somatization. Am J Psychiatry 1988;145:1358–1368.
7.
Schuepbach WMM, Adler RH, Sabbioni MEE: Accuracy of the clinical diagnosis of ‘psychogenic disorders’ in the presence of physical symptoms suggesting a general medical condition. Psychother Psychosom 2002;71:11–17.
8.
Oken D: Multiaxial diagnosis and psychosomatic model of disease. Psychosom Med 2000;62:171–175.
9.
Porcelli P, De Carne M, Fava GA: Assessing somatization in functional gastrointestinal disorders: Integration of different criteria. Psychother Psychosom 2000;69:198–204.
10.
Porcelli P, De Carne M: Criterion-related validity of the diagnostic criteria for psychosomatic research for alexithymia in patients with functional gastrointestinal disorders. Psychother Psychosom 2001;70:184–188.
11.
Grandi S, Fabbri S, Tossani E, Mangelli L, Branzi A, Magelli C: Psychological evaluation after cardiac transplantation: The integration of different criteria. Psychother Psychosom 2001;70:176–183.
12.
Sonino N, Navarrini C, Ruini C, Ottolini F, Paoletta A, Fallo F, Boscaro M, Fava GA: Persistent psychological distress in patients treated for endocrine disease. Psychother Psychosom 2004;73:78–83.
13.
Grassi L, Sabato S, Rossi E, Biancosino B, Marmai L: The use of the Diagnostic Criteria for Psychosomatic Research (DCPR) in oncology. Psychother Psychosom, in press.
14.
Haynes SN, Leisen MB, Blaine DD: Design of individualized behavioral treatment programs using functional analytic clinical case models. Psychol Assess 1997;9:334–348.
15.
Ringel Y, Drossman DA: From gut to brain and back. A new perspective into functional gastrointestinal disorders. J Psychosom Res 1999;47:205–210.
16.
Talley NJ, Spiller R: Irritable bowel syndrome: A little understood organic bowel disease? Lancet 2002;360:555–564.
17.
Drossman DA, Creed FH, Olden KW, Svedlund J, Toner BB, Whitehead WE: Psychosocial aspects of the functional gastrointestinal disorders. Gut 1999;45(suppl II):II25–II30.
18.
Bennett EJ, Palmer K, Badcock CA, Tennant CC, Kellow JE: Functional gastrointestinal disorders: Psychological, social, and somatic features. Gut 1998;42:414–420.
19.
Drossman DA (ed): The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology, and Treatment. Boston, Little, Brown, 1994.
20.
Porcelli P, Bagby RM, Taylor GJ, De Carne M, Leandro G, Todarello O: Alexithymia as a predictor of treatment outcome in patients with functional gastrointestinal disorders. Psychosom Med 2003;65:911–918.
21.
Mangelli L, Rafanelli C, Porcelli P, Fava GA: Interview for the Diagnostic Criteria of Psychosomatic Research (DCPR). Psychother Psychosom 2003;72:346–348.
22.
Svedlund J, Sjödin I, Dotevall G: GSRS. A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988;33:129–134.
23.
Veldhuyzen van Zanten SJO, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR: Design of treatment trials for functional gastrointestinal disorders. Gut 1999;45(suppl II):69–77.
24.
Agreus L, Svardsudd K, Nyren O, Tibblin G: Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time. Gastroenterology 1995;109:671–680.
25.
Foster SL, Cone JD: Validity issues in clinical assessment. Psychol Assess 1995;7:248–260.
26.
Taylor GJ, Bagby RM, Parker JDA: Disorders of Affect Regulation. Cambridge, Cambridge University Press, 1997.
27.
Porcelli P, Taylor GJ, Bagby RM, De Carne M: Alexithymia and functional gastrointestinal disorders. Psychother Psychosom 1999;68:263–269.
28.
Kosten TR, Krystal JH, Giller EL, Dan E: Alexithymia as a predictor of treatment response in post-traumatic stress disorder. J Traum Stress 1992;5:41–50.
29.
Bach M, Bach D: Predictive value of alexithymia: A prospective study in somatizing patients. Psychother Psychosom 1995;64:43–48.
30.
Taylor GJ: Recent developments in alexithymia theory and research. Can J Psychiatry 2000;45:134–142.
31.
Lumley MA, Stettner L, Wehmer F: How are alexithymia and physical illness linked? A review and critique of pathways. J Psychosom Res 1996;41:505–518.
32.
Kellner R: Psychosomatic Syndromes and Somatic Symptoms. Washington, American Psychiatric Press, 1991.
33.
Kroenke K, Spitzer RL, DeFruy FV, Hahn SR, Linzer M, Williams JBW, Brody D, Davis M: Multisomatoform disorder. An alternative to undifferentiated somatoform disorder for the somatizing patient in primary care. Arch Gen Psychiatry 1997;54:352–358.
34.
Bridges KW, Goldberg DP: Somatic presentation of DSM-III psychiatric disorders in primary care. J Psychosom Res 1985;29:563–569.
35.
Karlsson H, Joukamaa M, Lahti I, Lehtinen V, Kokki-Saarinen T: Frequent attender profiles: Different clinical subgroups among frequent attender patients in primary care. J Psychosom Res 1997;42:157–166.
36.
Barsky AJ, Klerman GL: Overview: Hypochondriasis, bodily complaints and somatic styles. Am J Psychiatry 1983;140:273–283.
37.
Frank JD, Frank JB: Persuasion and Healing. Baltimore, Johns Hopkins University Press, 1991.
38.
de Figuereido JM: Depression and demoralization: Phenomenological differences and research perspectives. Comp Psychiatry 1993;34:308–311.
39.
Slavney PR: Diagnosing demoralization in consultation psychiatry. Psychosomatics 1999;40:325–329.
40.
Engel GL: On looking inward and being scientific. A tribute to Arthur H. Schmale, MD. Psychother Psychosom 1990;54:63–69.
41.
Fava GA, Sonino N: Psychosomatic medicine: Emerging trends and perspectives. Psychother Psychosom 2000;69:184–197.
42.
von Ammon Cavanaugh: Depression in medically ill. Clinical issues in diagnostic assessment. Psychosomatics 1995;36:48–59.
43.
Conroy RM, Smyth O, Siriwardena R, Fernandes P: Health anxiety and characteristics of self-initiated general practitioner consultations. J Psychosom Res 1999;46:45–50.
44.
Bartolucci G, Savron G, Fava GA, Grandi S, Trombini G, Orlandi C: Psychological reactions to thermography and mammography. Stress Med 1989;5:195–199.
45.
Grandi S: The sequential parallel comparison model: A revolution in the design of clinical trials. Psychother Psychosom 2003;72:113–114.
46.
Fava M, Evins AE, Dorer DJ, Schoenfeld DA: The problem of the placebo response in clinical trials for psychiatric disorders: Culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003;72:115–127.
47.
Camilleri M: Therapeutic approach to the patient with irritable bowel syndrome. Am J Med 1999;107:27–32.
48.
Thompson WG: Gut Reactions. New York, Plenum, 1989.
49.
Klein KB: Controlled treatment in the irritable bowel syndrome: A critique. Gastroenterology 1988;95:232–242.
50.
Talley NJ, Phillips SF: Nonulcer dyspepsia: Potential causes and pathophysiology. Ann Intern Med 1988;108:865–879.
51.
Mearin F, Balboa A, Zarate N, Cucala M, Malagelada JR: Placebo in functional dyspepsia: Symptomatic, gastrointestinal motor, and gastric sensorial responses. Am J Gastroenterol 1999;94:116–125.
52.
Drossman DA, Thompson WG: Irritable bowel syndrome: A graduated, multi-component treatment approach. Ann Intern Med 1992;116:1009–1016.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.